ArticleThe oncologist2026
Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision Management of Tumor-Associated Fever: From Classification to Targeted Intervention.Cancer management and research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNeoplastic fever (NF) severely impairs quality of life and often limits antitumor therapy, yet effective treatment remains lacking. Given the central role of interleukin-6 (IL-6), we evaluated tocilizumab for NF management.
methodsWe retrospectively reviewed NF cases at 3 Chinese hospitals (2019-2023). Patients who received tocilizumab and had evaluable follow-up data were included in analyses of fever resolution, afebrile duration, Karnofsky Performance Status, inflammatory markers, antitumor outcomes, and adverse events (AEs). In patients with sequential exposure to non-steroidal anti-inflammatory drugs (NSAIDs) and tocilizumab, changes in inflammatory markers after each treatment were compared.
resultsForty-five patients were identified (median age 65). All had elevated CRP and IL-6. Among 22 treated with tocilizumab, all achieved fever resolution within 24 hours, sustained for ≥2 weeks, with significant reductions in CRP (mean, 95.7-19.0 mg/L) and other inflammatory markers. Median afebrile duration was 3 weeks, extended to 4 weeks with re-treatment. Systemic therapy was subsequently administered in patients with poor baseline performance, who achieved an objective response rate of 50%, a median progression-free survival of 11.6 months, and an overall survival of 21.3 months. AEs occurred in 81.8% (grade ≥3, 31.8%) but were manageable. Compared with NSAIDs, tocilizumab uniquely improved anemia and inflammatory control.
conclusionTocilizumab provided rapid and durable fever resolution with systemic anti-inflammatory effects, accompanied by functional and hematologic improvement. These findings suggest IL-6 blockade as a promising therapeutic option for NF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.